Postoperative endophthalmitis rates over the study period with subanalysis of endophthalmitis rates in cases with and without PCR and vitreous loss
| Year | Without intracameral moxifloxacin* | With intracameral moxifloxacin* | P value† | |||||||
| 2015 | 2016 | 2017 | 2018 January–May | Total | 2018 June–December | 2019 | 2020 January–March | Total | ||
| Study cases | 24 320 | 23 591 | 22 623 | 10 109 | 80 643 | 9702 | 16 524 | 5114 | 31 340 | |
| POE (%) | 27 (0.111) | 31 (0.131) | 39 (0.172) | 19 (0.188) | 116 (0.144) | 2 (0.020) | 6 (0.036) | 0 (0.0) | 8 (0.025) | <0.001 |
| PCR with V-loss (%) | 382 (1.57) | 385 (1.63) | 416 (1.84) | 174 (1.72) | 1357 (1.68) | 153 (1.58) | 264 (1.60) | 78 (1.52) | 495 (1.58) | |
| POE (%) | 2 (0.523) | 2 (0.519) | 3 (0.721) | 2 (1.149) | 9 (0.663) | 0 (0.0) | 1 (0.379) | 0 (0.0) | 1 (0.202) | 0.61 |
| PCR w/o V-loss | 23 938 | 23 206 | 22 207 | 9935 | 79 286 | 9549 | 16 260 | 5036 | 30 485 | |
| POE (%) | 25 (0.104) | 29 (0.125) | 36 (0.162) | 17 (0.171) | 107 (0.135) | 2 (0.020) | 5 (0.030) | 0 (0.0) | 7 (0.023) | <0.001 |
*Both groups received s/c gentamycin and dexamethasone injection after surgery.
†P values for difference in postoperative endophthalmitis rates between total cases in the two groups (with and without intracameral moxifloxacin). P values were adjusted using Bonferroni corrections
PCR, posterior capsular rupture; POE, postoperative endophthalmitis; V-loss, vitreous loss.